StreetSmart Live! Presents Michael Ballanger on 10/26/2020. Learn More

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Further Trial Data Analyses 'Reinforce' Profile of Biopharma's Multiple Sclerosis Drug

Research Report
  ()
The confirmatory results concerning Immunic's lead drug candidate IMU-838 are presented in an H.C. Wainwright & Co. report. read more >

Arrowhead Shares Point Higher on Positive Interim Data in Phase 2 Liver Disease Trial

  ()
Shares of Arrowhead Pharmaceuticals traded 48% higher after the firm reported positive interim results from its Phase 2 study of ARO-AAT in patients with alpha-1 antitrypsin deficiency liver disease. read more >

Marinus Pharma Shares Sail 50% Higher on Phase 3 Genetic Epilepsy Trial Results

  ()
Marinus Pharmaceuticals shares reached a new 52-week high price after the company reported it achieved the primary endpoint in its Phase 3 Study of ganaxolone for CDKL5 deficiency disorder, a rare type of genetic epilepsy. read more >

Immunomedics' Shares Double on Gilead's $21 Billion Buyout Offer

  ()
Shares of Immunomedics Inc. traded 100% higher after the company reported that it has agreed to be acquired by Gilead Sciences for $88 per share in cash. read more >

Intra-Cellular Shares Soar on Positive Bipolar Depression Study Findings

  ()
Shares of Intra-Cellular Therapies traded 77% higher after the company reported that positive data from its Phase 3 Study 402 will form the basis for its sNDA for lumateperone in treating bipolar depression in patients with Bipolar I or II disorder. read more >

Trillium Shares Get Boost from Dose Escalation Trial Data and Pfizer's $25 Million Equity Investment

  ()
Trillium Therapeutics shares traded 37% higher after the company reported updated results from its ongoing TTI-622 and TTI-621 Dose Escalation Studies along with a $25 million equity investment from Pfizer Inc. read more >

Biopharma Achieves 'Big Phase 3 Win' for its Pediatric Intrahepatic Cholestasis Drug

Research Report
  ()
The recent study results of Albireo Pharma's lead therapeutic candidate are discussed in an H.C. Wainwright & Co. report. read more >
News Update

Biotech Partners with University to Evaluate Psilocybin for Treating Methamphetamine Use Disorder

News Update
  ()
Revive Therapeutics reported it has entered into clinical trial agreement with the University of Wisconsin-Madison to evaluate the use of psilocybin for the treatment of methamphetamine use disorder. read more >
News Update

Life Sciences Firm Gains Protocol Approval for Phase 3 COVID-19 Study

News Update
  ()
Revive Therapeutics reported that a renowned independent institutional review board has approved its proposed Phase 3 clinical trial protocol for Bucillamine in COVID-19. read more >

Aimmune Therapeutics Shares Soar on Nestlé Health Science's $2.6 Billion Buyout

  ()
Aimmune Therapeutics shares traded 170% higher after the company reported it entered into a definitive agreement to be acquired by Nestlé for $34.50 per share in cash. read more >
News Update

Firm Submits Clinical Protocol for IRB Approval for Phase 3 COVID-19 Trial

News Update
  ()
Revive Therapeutics reported it submitted the clinical protocol for independent Institutional Review Board approval for its Phase 3 study of Bucillamine in COVID-19. read more >

VBI Shares Climb 34% After Identifying Two One-Dose COVID-19 Vaccine Candidates

  ()
VBI Vaccines shares traded higher after the company reported preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines. read more >

CytoDyn Receives the UK's MHRA Approval for Phase 3 COVID-19 Study

  ()
CytoDyn Inc. shares traded higher after the company reported it received authorization from the U.K.'s MHRA to proceed with its Phase 3 study of leronlimab in patients with severe-to-critical COVID-19. read more >

CureVac Shares Rise on Talks with EC to Supply 405 Million mRNA-Based COVID-19 Vaccine Doses

  ()
CureVac NV shares traded 13% higher after the company reported it is in advanced discussions with the European Commission to supply up to 405 million doses of a potential mRNA-based COVID-19 vaccine. read more >

Biotech Releases Positive Interim Results from Cystic Fibrosis Study

Research Report
  ()
This and other recent key events of AzurRx BioPharma are recapped in a ROTH Capital Partners report. read more >

California Biopharma to be Acquired by Sanofi for $3.6 Billion

Research Report
  ()
The deal is summarized and Principia Biopharma's Q2/20 clinical achievements are recapped in an H.C. Wainwright & Co. report. read more >

Momenta Pharmaceuticals Shares Rise 69% on $6.5 Billion Johnson & Johnson Takeover Bid

  ()
Shares of Momenta Pharmaceuticals set a new 52-week high after the company reported it entered into a definitive agreement with Johnson & Johnson to be acquired for $52.50 per share in cash. read more >
News Update

Pharmaceutical Firm Enrolls First US Patient in Phase 2b/3 Ifenprodil COVID-19 Trial

News Update
  ()
Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2. read more >

Mesoblast Shares Rocket Higher as FDA Committee Votes in Favor of Remestemcel-L for Pediatric SR-aGVHD Patients

  ()
Shares of Mesoblast Ltd. traded 50% higher after the company reported that the U.S. FDA's Oncologic Drugs Advisory Committee voted nine to one in favor of remestemcel-L (RYONCIL™) for efficacy in children with steroid-refractory acute graft versus host disease. read more >
News Update

Canadian Biotech Advances Antibodies, Diagnostics Programs in Q2/20

News Update
  ()
One highlight is ProMIS Neurosciences' development of a SARS CoV-2 antibody test. read more >
News Update

Life Sciences Firm Signs MOU for Phase 3 COVID-19 Study

News Update
  ()
Revive Therapeutics reported it signed a MOU with Attwill Medical Solutions Sterilflow to be a clinical packaging and distribution resource for its Phase 3 clinical trial of Bucillamine in COVID-19. read more >
News Update

Biotech Develops Oral Film Strips for Psychedelic Medicine Delivery

News Update
  ()
This development is a technical milestone for Revive Therapeutics and its drug delivery technology. read more >

Eyenovia Shares Look 38% Higher on Development Deal with Arctic Vision in Asia

  ()
Shares of Eyenovia Inc. set a new 52-week high after the firm reported it entered into an exclusive collaboration and license agreement with Arctic Vision to develop and market MicroPine and MicroLine in China and South Korea. read more >

Seres Therapeutics Shares Go Parabolic on Positive Topline Data from Phase 3 C.Diff Trial

  ()
Seres Therapeutics shares traded 350% higher setting a new 52-week high after the firm reported positive topline results from its SER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection. read more >

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space?

Contributed Opinion
  ()
Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile. read more >
Showing Results: 26 to 50 of 122 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts